scholarly article | Q13442814 |
P2093 | author name string | Michael Soltis | |
Arthur J Olson | |||
Stefano Forli | |||
John H Elder | |||
Ana Gonzalez | |||
Theresa Tiefenbrunn | |||
Yingssu Tsai | |||
Meaghan Happer | |||
Charles D Stout | |||
P2860 | cites work | Fragment screening and HIV therapeutics | Q26826945 |
Fragment-Based Screen against HIV Protease | Q27663595 | ||
Systematic investigation of halogen bonding in protein-ligand interactions | Q27666413 | ||
Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease | Q27677124 | ||
Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 | Q27678152 | ||
XDS | Q27860472 | ||
Integration, scaling, space-group assignment and post-refinement | Q27860550 | ||
Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines | Q27860952 | ||
Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
Features and development of Coot | Q27861079 | ||
The CCP4 suite: programs for protein crystallography | Q27861090 | ||
Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo | Q28379312 | ||
AutoDrug: fully automated macromolecular crystallography workflows for fragment-based drug discovery | Q36806971 | ||
Differential evolution for protein crystallographic optimizations. | Q51983208 | ||
A phased translation function | Q56877546 | ||
P433 | issue | 2 | |
P921 | main subject | drug discovery | Q1418791 |
P304 | page(s) | 141-8 | |
P577 | publication date | 2014-02-01 | |
P1433 | published in | Chemical Biology and Drug Design | Q15749458 |
P1476 | title | Crystallographic Fragment-Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease | |
P478 | volume | 83 |
Q27728053 | A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413 |
Q35848043 | Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery |
Q41229438 | Contemporary Use of Anomalous Diffraction in Biomolecular Structure Analysis |
Q40467926 | Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals. |
Q41989179 | Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease |
Q59355901 | Flap-site Fragment Restores Back Wild-type Behaviour in Resistant form of HIV Protease |
Q38587368 | Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities |
Q35181268 | Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery |
Q28552598 | Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection |
Q57022956 | Proteases: Pivot Points in Functional Proteomics |
Q36438686 | Rapid experimental SAD phasing and hot-spot identification with halogenated fragments |
Q36006936 | Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library |
Q40578605 | Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein-ligand binding challenge |